Alector soars on Genentech deal for experimental Parkinson's drug

By Reuters News

** Shares of drug maker Alector ALEC.O surge 44.20% to $2.61 premarket

** Co enters global licensing deal with Genentech for AL050, ALEC's experimental drug for Parkinson's disease

** ALEC grants Genentech exclusive global rights to develop and commercialize AL050

** The deal brings $100 million upfront and is eligible for up to $1.17 billion in milestone payments into 2029 - ALEC

** Co retains ownership of its ABC platform, its technology platform for developing neurodegenerative disease therapies, and full rights for pipeline use

** As of last close, ALEC up 16.03%

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.
The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.
To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.
 

Cryptocurrency-related content is intended solely as news and market commentary. Crypto Derivatives are not available to Retail clients registered with Capital Com (UK) Ltd.